Related references
Note: Only part of the references are listed.BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Marco H. Hofmann et al.
CANCER DISCOVERY (2021)
Mechanisms of Resistance to KRASG12C Inhibitors
Victoria Dunnett-Kane et al.
CANCERS (2021)
Searching for treatments for non-G12C-KRAS mutant cancers
Christina Guo et al.
BRITISH JOURNAL OF CANCER (2021)
SOS2 Comes to the Fore: Differential Functionalities in Physiology and Pathology
Fernando C. Baltanas et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Novel anthraquinone compounds as anticancer agents and their potential mechanism
Wei Tian et al.
FUTURE MEDICINAL CHEMISTRY (2020)
RAS, wanted dead or alive: Advances in targeting RAS mutant cancers
Clint A. Stalnecker et al.
SCIENCE SIGNALING (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
SOS GEFs in health and disease
Fernando C. Baltanas et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2020)
Progress in targeting RAS with small molecule drugs
Frank McCormick
BIOCHEMICAL JOURNAL (2019)
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction
Roman C. Hillig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Drugging an undruggable pocket on KRAS
Dirk Kessler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Cracking KRAS
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2019)
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
Neha Bansal et al.
CARDIO-ONCOLOGY (2019)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
An oxanthroquinone derivative that disrupts RAS plasma membrane localization inhibits cancer cell growth
Lingxiao Tan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Regulation of Ras signaling and function by plasma membrane microdomains
Lawrence E. Goldfinger et al.
BIOSCIENCE TRENDS (2017)
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Jonathan M. L. Ostrem et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Sos1 disruption impairs cellular proliferation and viability through an increase in mitochondrial oxidative stress in primary MEFs
P. Liceras-Boillos et al.
ONCOGENE (2016)
Rational Design of Small Molecule Inhibitors Targeting the Ras GEF, SOS1
Chris R. Evelyn et al.
CHEMISTRY & BIOLOGY (2014)
An overview of doxorubicin formulations in cancer therapy
Sangeeta Rivankar
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Doxorubicin Cardiomyopathy
Kanu Chatterjee et al.
CARDIOLOGY (2010)
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?
Dominico Vigil et al.
NATURE REVIEWS CANCER (2010)
Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: Predictiveness and pitfalls
J. Robert
CELL BIOLOGY AND TOXICOLOGY (2007)
Ras-guanine nucleotide exchange factor Sos2 is dispensable for mouse growth and development
LM Esteban et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Share Paper
